Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39 th Annual Meeting 2024 November 06, 2024 09:00 ...

However, their use in RNA therapeutics has remained largely undeveloped due to the challenges of constructing supraparticles that are both structurally precise and biologically functional. A ... the ...

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Keylicon Biosciences is pleased to announce its exclusive rights to a groundbreaking next-generation RNA technology developed at Boston University. This ...

Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for ...

RNA viruses are renowned for their elegant structure and finely tuned self‐assembly processes, which are critical both for viral life cycles and for potential applications in nanotechnology and ...

Credit Liu, J., McRae, E.K.S., Zhang, M. et al. Non-averaged single-molecule tertiary structures reveal RNA self-folding through individual-particle cryo-electron tomography.

The global self-amplifying ribonucleic acid (RNA) synthesis market is projected to reach $310.8m by 2030 at a compound annual growth rate of 19.24%, according to Research and Markets.

Our cells need to be able to recognize potential invaders as a threat, the key function of the body's innate immune system. Sometimes this process fails, causing the body to react to its own cells ...